Vaccines

Ultragenyx's stock plummets after its Osteogenesis Imperfecta drug fails to reduce fractures, a major blow for patients and a test of the firm's pipeline.

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

After resolving a key manufacturing issue, Unicycive has resubmitted its kidney drug NDA, offering new hope for dialysis patients with a lower pill burden.

Mirum raises over a quarter-billion dollars to acquire Bluejay Therapeutics, targeting a high-potential liver disease drug and signaling major growth.

Alvotech and Teva's settlement with Regeneron for an Eylea biosimilar paves the way for a 2026 launch, promising increased competition and lower costs.

A new oral drug, cadisegliatin, enters a major clinical trial in the UAE, aiming to help Type 2 diabetes patients struggling with insulin therapy.

Millions struggle to swallow pills. Azurity's new FDA-approved liquid hypertension drug, Javadin, offers a ready-to-use solution for better adherence.

Avantor appoints financial heavyweight Simon Dingemans to its board, a strategic move to accelerate its ambitious turnaround amid market pressures.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

Molecular Partners readies for a pivotal presentation at the J.P. Morgan conference, showcasing its next-gen DARPin therapeutics for hard-to-treat cancers.

Incyte's Minjuvi, a first-of-its-kind immunotherapy, gains EC approval for follicular lymphoma, offering patients a powerful new chemo-free option.

A Phase 1 trial for Moleculin's WP1066 shows encouraging safety and anti-tumor activity for children with deadly brain tumors like DIPG.

New data reveals a novel therapy shrinks tumors in salivary gland cancer, offering hope where few options exist and validating a new oncology platform.

New data shows Vyriad's VV169 eliminated myeloma in mice without severe toxicity, signaling a potential shift to safer, scalable 'off-the-shelf' CAR T.

Pfizer projects lower 2026 earnings as COVID sales wane and patents expire, shifting focus to a multi-billion dollar R&D push for future growth.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

IO Biotech’s cancer vaccine posts impressive 5-year survival data, but a narrow miss in its pivotal trial creates an uncertain path in a competitive market.

Anixa Biosciences now fully controls its breast cancer vaccine after promising Phase 1 data. What does this strategic move mean for investors and medicine?

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.